148.  A bacteriophage capsid protein provides a general amyloid interaction motif (GAIM) that binds and remodels misfolded protein assemblies.  Krishnan R, Tsubery H, Proschitsky MY, Asp E, Lulu M, Gilead S, Gartner M, Waltho JP, Davis PJ, Hounslow AM, Kirschner DA, Inouye H, Myszka DG, Wright J, Solomon B, Fisher RA. J Mol Biol. (2014) 26;426(13):2500-2519.



147.  Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design.  Christopher JA, Brown J, Doré AS, Errey JC, Koglin M, Marshall FH, Myszka DG, Rich RL, Tate CG, Tehan B, Warne T, Congreve M.    J Med Chem. (2013) 56(9):3446-3455.


146. CCR5 is a receptor for Staphylococcus aureus leukotoxin.  ED,Alonzo F 3rd, Kozhaya L, Rawlings SA, Reyes-Robles T, DuMont AL, Myszka DG, Landau NR, Unutmaz D, Torres VJ (2013)  Nature 493:51-55.

145. Interactions of the Human LIP5 Regulatory Protein with Endosomal Sorting Complexes Required for Transport.  Skalicky JJ, Arii J, Wenzel DM, Stubblefield WM, Katsuyama A, Uter NT, Bajorek M, Myszka DG, Sundquist WI (2012)  J Biol Chem. 287:43910-43926.

144. Structure of a Proteasome Pba1-Pba2 Complex.  Stadtmueller BM, Kish-Trier E, Ferrell K, Petersen CN, Robinson H, Myszka DG, Eckert DM, Formosa T, Hill CP (2012)  J Biol Chem. 287:37371-37382.

143. Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without phage or cell surface display.  Votsmeier C, Plittersdorf H, Hesse O, Scheidig A, Strerath M, Gritzan U, Pellengahr K, Scholz P, Eicker A, Myszka DG, Coco WM, Haupts U (2012) MAbs 4:341-348.

142. Exploring the horizons of small molecule drug discovery the evolution and application of the ideal fragment library.  Myszka DG & Paul J (2012) Drug Discovery World 2011/12 51-58.

141. Survey of the 2009 commercial optical biosensor literature.  Rich RL & Myszka DG (2011)  J. Mol. Recog. 24:892-914.

140. Fragment screening of stabilized G-protein coupled receptors using biophysical methodsCongreve M, Rich RL, Myszka DG, Siegal G & Marshall F (2011) Methods Enzymol. 493:115-136.

139. The revolution of real-time, label-free biosensor applications in Label-Free Technologies.  Rich RL & Myszka DG (2011)  in Drug Discovery pp. 1-26.

138. Two independent histidines, one in human prolactin and one in its receptor, are critical for pH dependent receptor recognition and activation.  Kulkarni MV, Tettamanzi MC, Murphy JW, Keeler C, Myszka DG, Chayen NE, Lolis EJ & Hodsdon ME (2010) J. Biol. Chem. 285: 38524-38533.

137. Biacore analysis with stabilized GPCRs. Rich RL, Errey J, Marshall F & Myszka DG (2010) Anal. Biochem 409: 267-272.

136.  Biosensor-based fragment screening using FastStep injections.  Rich RL, Quinn JG, Morton T, Stepp JD & Myszka DG (2010) Anal. Biochem. 407: 270-277.

135. Grading the commercial optical biosensor literature – Class of 2008: “The Mighty Binders”.  Rich RL & Myszka DG (2010)  J. Mol. Recog. 23: 1-64.

134. Structural models for interactions between the 20S proteasome and its PAN/19S activators.  Stadtmueller BM, Ferrell K, Whitby FG, Heroux A, Robinson H, Myszka DG, Hill CP (2010)  J. Biol. Chem. 285: 13-17.

133. Characterizing high-affinity antigen-antibody complexes by kinetic and equilibrium based methods.  Drake AW, Myszka DG & Klakamp SL (2010) in Current Trends in Monoclonal Antibody Development and Manufacturing, pp. 179-192.

132. Jay JI, Lai BE, Myszka DG, Mahalingam A, Langheinrich K, Katz DF & Kiser PF (2010) Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors, Mol. Pharm. 7: 116-129.

131. Kinetic analysis and fragment screening with FujiFilm AP- 3000.  Rich RL & Myszka DG (2010) Anal. Biochem. 402: 170-178.

130. Exploring minimal biotinylation conditions for biosensor analysis using CAP chips.  Papalia GA & Myszka DG (2010) Anal. Biochem. 403: 30-35.

129. Direct DNA methylation profiling using methyl binding domain proteins.  Yu Y, Blair S, Gillespie D, Jensen R, Myszka D, Badran AH, Ghosh I, Chagovetz A (2010) Anal. Chem. 82: 5012-5019. 

128. Structural basis for ESCRT-III protein autoinhibition.  Bajorek M, Schubert HL, McCullough J, Langelier C, Eckert DM, Stubblefield W-MB, Uter NT, Myszka DG, Hill CP & Sundquist WI (2009) Nat. Struct. Mol. Biol. 16: 754-762.

127. E2 interaction and dimerization in the crystal structure of TRAF6.  Yin Q, Lin SC, Lamothe B, Lu M, Lo YC, Hura G, Zheng L, Rich RL, Campos AD, Myszka DG, Lenardo MJ, Darnay BG & Wu H (2009) Nat. Struct. Mol. Biol. 16: 658-666.

126.  Inhibition and binding kinetics of the Hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior.  Rajagopalan R, Misialek S, Stevens S, Myszka D, Brandhuber B, Ballard J, Andrews S, Seiwert S, Kossen K (2009)Biochemistry 48: 2559-2568.

125. “Spot and Hop” – Internal referencing for surface plasmon resonance imaging using a three-dimensional microfluidic flow cell array.  Eddings MA, Eckman JW, Arana CA, Connolly JE, Papalia GA, Gale BK, Myszka DG (2009)  Anal. Biochem. 385: 309-313.

124. Detergent screening of a GPCR using serial and array biosensor technologies.   Rich RL, Miles AR, Gale BK, Myszka DG (2009) Anal. Biochem. 386: 98-104.

123. A global benchmark study using affinity-based biosensors. Rich et al., (2009) Anal. Biochem. 386: 194-216.

122. Extracting affinity constants from biosensor binding responses in Label-Free Biosensors.  Rich RL, Myszka DG (2009)  Techniques and Applications pp 48-84.

121. Extracting kinetic rate constants from biosensor binding responses in Label-Free Biosensors.  Rich RL, Myszka DG (2009)  Techniques and Applications pp 85-109.

120. Extracting kinetic rate constants from surface plasmon resonance array systems.  Rich RL, Cannon MJ, Jenkins J, Pandian P, Sundaram S. Magyar R, Brockman J, Lambert J, Myszka DG (2008) Anal. Biochem. 373: 112-120.

119. Continuous flow microfluidic printing of proteins for array-based applications including surface plasmon resonance imaging.  Natarajan S, Katsamba PS, Miles A, Eckman J, Papalia GA, Rich RL, Gale B, Myszka DG (2008) Anal. Biochem. 373: 141-146.

118. Structural and functional studies of ALIX interactions with YPXnL late domains of HIV-1 and EIAV, Zhai Q, Fisher RD, Chung H-Y, Myszka DG, Sundquist WI & Hill CP (2008) Nature Struct. Biol. 15: 43-49.

117. High-affinity interaction between IKKβ and NEMO.  Lo Y-C, Maddineni U, Chung JY, Rich RL, Myszka DG, Wu H (2008) , Biochemistry 47: 3109-3116.

116. Binding characterization of the IL-13 signaling complex and development of a ternary TR-FRET assay.  Yang X, Lee J, Brooks J, Wilhelm J, Myszka D, Kasaian MT, Goldman S, Wolf S, Fitz LJ (2008) Anal. Biochem. 376: 206-212.

115. Surface plasmon resonance biosensors.  Homola J, Yee SS, Myszka D (2008) Optical Biosensors (2nd Ed) pp. 185-242.

114. Probing membrane protein interactions with real-time biosensor technology.  Navratilova I, Myszka DG, Rich RL (2008) in Biophysical Analysis of Membrane Proteins (E. Pebay- Peroula, Ed.) p 121-140.

113. Improved continuous-flow print head for micro-array deposition.  Eddings MA, Miles AR, Eckman JW, Kim J, Rich RL, Gale BK, Myszka DG (2008)  Anal. Biochem. 382: 55-59.

112. Thermodynamic characterization of pyrazole and azaindole derivatives binding to p38 MAP kinase using Biacore T100 technology and van’t Hoff analysis.  Papalia GA, Giannetti AM, Arora N, Myszka DG (2008)  Anal. Biochem. 383: 255-264.

111. Survey of the year 2007 commercial optical biosensor literature. Rich RL, Myszka DG (2008) J. Mol. Recog. 21: 355-400.

110. Optimal conditions for protein array deposition using continuous flow.  Natarajan S, Hatch A, Myszka DG, Gale BK (2008)  Anal. Chem. 80: 8561-8567.

109.  Survey of the year 2006 commercial optical biosensor literature.  Rich RL, Myszka DG (2007) J. Mol. Recog. 20: 300-366.

108. XIAP mediates survival through the BIR1/TAB1 interaction and BIR1 dimerization.  Lu M, Lin S-C, Huang Y, Kang Y, Rich RL, Myszka DG, Han J, Wu H (2007) Mol. Cell 26: 689-702.

107. Molecular basis for passive immunotherapy of Alzheimer's disease.  Gardberg A, Dice L, Helmbrecht E, Ko J, Ou S, Patterson P, Rich RL, Myszka DG, Wetzel R, Dealwis C (2007)  Proc. Natl Acad. Sci. USA 104: 15659-15664.

106. Label-free characterization of nuclear receptor/co-regulator peptide interactions in an array format. Katsamba P, Myszka DG, Persson B & Rich RL (2007) Peptide Science 2006: Proc. Japanese Peptide Soc. 43: 350-351.

105. Thermodynamic benchmark study using Biacore technology.  Navratilova I, Papalia GA, Rich RL, Bedinger D, Brophy S, Condon B, Deng T, Emerick AW, Guan H-W, Hayden T, Heutmekers T, Hoorelbeke B, McCroskey MC, Murphy MM, Nakagawa T, Parmeggiani F, Qin X, Rebe S, Tomasevic N, Tsang T, Waddell MB, Zhang FF, Leavitt S & Myszka DG (2007) Anal. Biochem. 364: 67-77.

104. The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range.  Keeler C, Jablonski EM, Albert YB, Taylor BD, Myszka DG, Clevenger CV & Hodsdon ME (2007) The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range, Biochemistry 46: 2398-2410.

103. Higher-throughput, label-free, real-time molecular interaction analysis. Rich RL & Myszka DG (2007) Anal. Biochem. 361: 1-6.

102. Surface plasmon resonance biosensors' contributions to proteome mapping.  Rich RL & Myszka DG (2006) Spectral Techniques in Proteomics pp. 287-304.

101. High-resolution characterization of antibody fragment/antigen interactions using Biacore T100.  Papalia G, Baer M, Luehrsen K, Nordin H, Flynn P & Myskza DG (2006)  Anal. Biochem. 359: 112-119.

100. Survey of the year 2005 commercial optical biosensor literature.  Rich RL & Myszka DG (2006)  J. Mol. Recog. 19: 478-534.

99.  Comparative analysis of ten small molecules binding to carbonic anhydrase II by different investigators using Biacore technology.  Papalia G, Leavitt S, Bynum M, Katsamba P, Wilton R, Qiu H, Steuker sM, Wang S, Bindu L, Phogat S, Giannetti A, Ryan T, Pudlak V, Matusiewicz K, Michelson K, Nowakowski A, Pham Baginski A, Brooks J, Tieman B, Bruce B, Vaughn M, Baksh M, Cho Y, De Wit M, Smets A, Vandersmissen J, Michiels L & Myszka DG (2006) Anal. Biochem. 359: 94-105.

98. Exploring 'oneshot' kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. Bravman T, Bronner V, Lavie K, Notcovich A, Papalia G & Myszka DG (2006)  Anal. Biochem. 358: 281-288.

97.  A theoretical and experimental study of competition between solution and surface receptors for ligand in a biacore flow cell. He X, Coombs D, Myszka DG & Goldstein B (2006)Bull. Math. Biol. 68: 1125-1150.

96. Analyzing ligand and small molecule binding activity of solubilized GPCRs using biosensor technology.  Navratilova I, Dioszegi M & Myszka DG (2006) Anal. Biochem. 355: 132-139.

95. Screening antibodyantigen interactions in parallel using Biacore A100.  Säfsten P, Klakamp S, Drake A, Karlsson R & Myszka DG (2006) Anal. Biochem. 353: 181-190.

94. A biosensor-based approach toward purification and crystallization of G protein-coupled receptors.  Navratilova I, Pancera M, Wyatt R & Myszka DG (2006)  Anal. Biochem. 353: 278-273.

93. A novel PDMS microfluidic spotter for fabrication of protein chips and microarrays.  Chang-Yen D, Myszka D & Gale B (2006) J Microelectromech. Syst. 15: 1145-1151.

92. Investigating biomolecular interactions and binding properties using SPR biosensors.  Navratilova I & Myszka DG (2006)  in Springer Ser. Chem. Sens. Biosens. (Surface Plasmon Resonance Based Sensors) 4: 155-176.

91. Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore users.  Katsamba P, Navratilova I, Calderon-Cacia M, Fan L, Thornton K, Zhu M, Vanden Bos T, Forte C, Friend D, Laird-Offringa I, Tavares G, Whatley J, Shi E, Widom A, Lindquist K, Klakamp S, Drake A, Bohmann D, Roell M, Rose L, Dorocke J, Roth B, Luginbühl B & Myszka DG (2006) Anal. Biochem. 352: 208-221.

90. Analyzing a kinetic titration series using affinity biosensors. Karlsson R, Katsamba P, Nordin H, Pol E & Myszka DG (2006) Anal. Biochem. 349: 136-147.

89. Eosinophil-granule major basic protein, a C-type lectin, binds heparin. Swaminathan G, Myszka DG, Katsamba P, Ohnuki L, Gleich G & Acharya K (2005) Biochemistry 44: 14152-14158.

88. Survey of the year 2004 commercial optical biosensor literature. Rich RL & Myszka DG (2005). J. Mol. Recog. 18: 431-478.

87. The interaction between tBid and cardiolipin or monolysocardiolipin. Liu J, Durrant D, Yang H, He Y, Whitby F, Myszka DG & Lee R (2005) Biochem. Biophys. Res. Commun. 330: 865-870.

86. Phosphoinositide-containing polymerized liposomes: stable membrane-mimetic vesicles for
 protein-lipid binding analysis.  Ferguson C, James R, Bigman C, Shepard D, Abdiche Y, Katsamba P, Myszka DG & Prestwich G (2005) Bioconj. Chem. 16: 1475-1483.

85. Affinity-based optical biosensors. Long SD & Myszka DG (2005) in Handbook of Affinity Chromatography 685-698.

84. Measuring long association phases.  Navratilova I, Eisenstein E & Myszka DG (2005)  Anal. Biochem. 344: 295-297.

83. Survey of the year 2003 commercial optical biosensor literature.  Rich RL & Myszka DG (2005)  J. Mol. Recog. 18: 1-39.

82. Utilizing surface plasmon resonance for the discovery and development of therapeutic antibodies.  Cannon MJ & Myszka DG (2005)  in Methods for Structural Analysis of Protein Pharmaceuticals pp.533-550.

81. Solubilization, stabilization, and purification of chemokine receptors using Biacore technology.  Navratilova I, Sodroski J & Myszka DG (2005) Anal. Biochem. 339: 271-281.

80. Crystal structure of the PHBEACH domains of human LRBA/BGL.  Gebauer D, Li J, Jogl G, Shen Y, Myszka DG & Tong L (2004)  Biochemistry 43: 14873-14880.

79. Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods.  Drake A, Myszka DG & Klakamp S (2004)  Anal. Biochem. 328: 35-43.

78. Kinetic screening of antibodies from crude hybridoma samples using Biacore. Canziani GA, Klakamp S & Myszka DG (2004) Anal. Biochem. 325: 301-307.

77. Kinetic analysis of Aβ fibril elongation. Cannon MJ, Williams A, Wetzel R & Myszka DG (2004) Anal. Biochem. 328: 67-75.

76. Probing the mechanism of drug/lipid membrane interactions using Biacore, Abdiche YN & Myszka DG (2004) Anal. Biochem. 328: 233-243.

75. Why you should be using more SPR biosensor technology, Rich RL & Myszka DG (2004) Drug Discovery Today: Technologies 1: 301-308.